HACKENSACK, N.J., Sept. 7, 2012 /PRNewswire/ -- Champions Oncology, Inc. (OTC: CSBR) announced that Joel Ackerman, Champions CEO, will present at the Rodman & Renshaw Annual Global Investment Conference, on Monday, September 10, 2012 at 2:50 PM ET. The conference will be held September 9-11, 2012 at the Waldorf Astoria Hotel in New York City.
A webcast of the audio portion of the presentation will be available at www.championsoncology.com on the Investors tab.
About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company's Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or Tumorgrafts, in a manner that preserves the biological characteristics of the original human tumor. The Company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions ("POS") in which physicians and patients looking for information help guide the development of personalized treatment plans, and Translational Oncology Solutions ("TOS") in which pharmaceutical and biotech companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs and increasing the adoption of existing drugs. The Company's Tumorgraft Technology Platform consists of processes, physical tumors and information that we use to personalize the development and use of oncology drugs. The Company is building its Tumorgraft Technology Platform through the procurement, development and characterization of numerous Tumorgrafts within each of several cancer types. Tumorgrafts are procured